The clinical outcomes of COVID-19 critically ill patients co-infected with other respiratory viruses: a multicenter, cohort study

BMC Infectious Diseases

Research

Ibrahim Al Sulaihim¹  Meshari M. Alanizy²  Sarah A. Almuqbil³  Mai Alalawi⁴  Albandari Alghamdi⁵  Ghazwa B. Korayem⁵  Nirvana Alnajjar⁵  Rand Alotaibi⁵  Alaa Alhubaishi⁵  Ahad Alawad⁵  Ohoud Aljuhani⁶  Mohammad Bosaeed⁷  Ramesh Vishwakarma⁸  Khalid Bin Saleh⁹  Hisham A. Badreldin⁹  Khalid Al Sulaiman^1,10  Fatimah Alhassan^1,11  Walaa A. Sait^1,12  Samiah Alsohimi^1,13  Ahlam H. Alharbi^1,14  Abeer A. Alenazi^1,14  Ali F. Altebainawi^1,15  Suliman Alghnam^1,16 

[1] Central Security Hospital, Riyadh, Saudi Arabia;College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, PO Box 22490, 11426, Riyadh, Saudi Arabia;College of Pharmacy, Qassim University, Qassim, Saudi Arabia;Department of Pharmaceutical Sciences, Fakeeh College for Medical Sciences, Jeddah, Saudi Arabia;Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O.Box 84428, 11671, Riyadh, Saudi Arabia;Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia;Infectious Disease Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia;College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia;Norwich Medical School, University of East Anglia, Norwich, UK;Pharmaceutical Care Department, King Abdulaziz Medical City (KAMC)-Ministry of National Guard Health Affairs (MNGHA), Riyadh, Saudi Arabia;College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, PO Box 22490, 11426, Riyadh, Saudi Arabia;King Abdullah International Medical Research Center, Riyadh, Saudi Arabia;Pharmaceutical Care Department, King Abdulaziz Medical City (KAMC)-Ministry of National Guard Health Affairs (MNGHA), Riyadh, Saudi Arabia;College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, PO Box 22490, 11426, Riyadh, Saudi Arabia;King Abdullah International Medical Research Center, Riyadh, Saudi Arabia;Saudi Critical Care Pharmacy Research (SCAPE) Platform, Riyadh, Saudi Arabia;Pharmaceutical Care Department, King Abdulaziz Medical City (KAMC)-Ministry of National Guard Health Affairs (MNGHA), Riyadh, Saudi Arabia;King Abdullah International Medical Research Center, Riyadh, Saudi Arabia;Pharmaceutical Care Department, King Abdulaziz Medical City, Jeddah, Saudi Arabia;Pharmaceutical Care Department, King Abdulaziz University Hospital, Jeddah, Saudi Arabia;Pharmaceutical Care Department, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia;Pharmaceutical Care Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia;Pharmaceutical Care Services, King Khalid Hospital, Hail Health Cluster, Hail, Saudi Arabia;Population Health Section, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia;

关键词: Coronavirus disease;    COVID19;    Critically ill;    Coinfection;    Outcomes;    Mortality;    MV duration;    Respiratory viruses;   

DOI  :  10.1186/s12879-023-08010-8

 received in 2022-07-10, accepted in 2023-01-17,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundPrevious studies have shown that non-critically ill COVID-19 patients co-infected with other respiratory viruses have poor clinical outcomes. However, limited studies focused on this co-infections in critically ill patients. This study aims to evaluate the clinical outcomes of critically ill patients infected with COVID-19 and co-infected by other respiratory viruses.MethodsA multicenter retrospective cohort study was conducted for all adult patients with COVID-19 who were hospitalized in the ICUs between March, 2020 and July, 2021. Eligible patients were sub-categorized into two groups based on simultaneous co-infection with other respiratory viruses throughout their ICU stay. Influenza A or B, Human Adenovirus (AdV), Human Coronavirus (i.e., 229E, HKU1, NL63, or OC43), Human Metapneumovirus, Human Rhinovirus/Enterovirus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Parainfluenza virus, and Respiratory Syncytial Virus (RSV) were among the respiratory viral infections screened. Patients were followed until discharge from the hospital or in-hospital death.ResultsA total of 836 patients were included in the final analysis. Eleven patients (1.3%) were infected concomitantly with other respiratory viruses. Rhinovirus/Enterovirus (38.5%) was the most commonly reported co-infection. No difference was observed between the two groups regarding the 30-day mortality (HR 0.39, 95% CI 0.13, 1.20; p = 0.10). The in-hospital mortality was significantly lower among co-infected patients with other respiratory viruses compared with patients who were infected with COVID-19 alone (HR 0.32 95% CI 0.10, 0.97; p = 0.04). Patients concomitantly infected with other respiratory viruses had longer median mechanical ventilation (MV) duration and hospital length of stay (LOS).ConclusionCritically ill patients with COVID-19 who were concomitantly infected with other respiratory viruses had comparable 30-day mortality to those not concomitantly infected. Further proactive testing and care may be required in the case of co-infection with respiratory viruses and COVID-19. The results of our study need to be confirmed by larger studies.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 2

42004_2023_830_Article_IEq36.gif